Psychedelics to help cancer patients

 

Researchers are studying the use of psychedelics to treat a number of mental health conditions (Adobe Stock).

Psychedelics such as psilocybin, LSD, and MDMA show promise in significantly reducing depression and anxiety symptoms in patients with advanced cancer compared to available prescription antidepressants. 

 A meta-analysis of five clinical trials revealed that psychedelic medications alone reduced depression scores and anxiety scores, as measured by standardized inventories.

  • One trial showed that 60% of cancer patients who received a high-dose psilocybin session achieved clinical remission for depression, compared to 16% in the placebo group.
  • Psychedelic therapy may be more effective in addressing underlying trauma associated with a cancer diagnosis and treatment, potentially offering advantages over traditional prescription antidepressants.
  • Patients reported that psychedelic sessions helped them process repressed emotions, leading to acceptance and reduced feelings of isolation.
  • Further research is needed to explore the effectiveness of psychedelics in treating anxiety and depression in cancer patients and those with other life-threatening diseases.
  • Regulatory challenges remain, as psychedelics are classified as Schedule 1 drugs in the U.S., limiting their medical use despite the precedent set by the FDA's approval of cannabidiol for rare childhood seizure disorders.

Post a Comment

Previous Next

Contact Form